Ferric carboxymaltose for iron-deficiency anemia secondary to gastrointestinal bleeding: a systematic review and meta-analysis.

A comprehensive search across multiple databases identified randomized controlled trials comparing ferric carboxymaltose with other iron formulations.

The overall incidence of drug-related adverse events was comparable between groups (risk ratio = 0.82, 95% CI: 0.51-1.34); however, ferric carboxymaltose was associated with a substantially increased risk of hypophosphatemia (risk ratio = 21.00, 95% CI: 8.90-49.56).